替比夫定治疗HBeAg阳性慢性乙型肝炎52周不同时期疗效分析  

Efficacy of telbivudine treatment of patients with HBeAg-positive chro nic hepatitis B for 52 weeks

作　　者：徐静[1] 李宜[1] 

机构地区：[1]安徽医科大学附属省立医院感染病科,安徽合肥230001

出　　处：《中西医结合肝病杂志》2013年第4期206-208,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:评价替比夫定治疗慢性乙型肝炎52周不同时期疗效。方法:采用替比夫定每日600mg一次口服治疗82例慢性乙型肝炎患者52周,对治疗前,治疗后4周、12周、24周、36周、48周、52周时HBV DNA检测不到率、丙氨酸转氨酶(ALT)复常率、HBeAg阴转率及血清转换率进行比较。结果:与治疗前相比,替比夫定治疗4周后HBV DNA检测不到率、ALT复常率明显升高,治疗12周后HBeAg阴转率、治疗36周后HBeAg血清转换率明显升高,52周分别达95.12%、95.12%、56.1%、32.93%,差异均有显著性意义(P<0.05)。结论:替比夫定治疗慢性乙型肝炎疗效好,有一定时效关系。Objective： To evaluate the efficacy of telbivudine treatment of patients with HBeAg-positive chronic hepatitis B for 52 weeks. Methods： Eighty-two patients treated with telbivudine 600mg qd PO for 52 weeks were enrolled. The rates of HBV DNA undetectable, ALT normalizition, HBeAg loss .and seroconversion were compared before and after 4, 12, 24, 36, 48, 52 weeks of treatment. Results： Compared with before treatment , the rates of HBV DNA undetectable, ALT normalizition at af- ter 4 weeks and HBeAg loss at after 12 weeks, HBeAg seroconversion at after 36 weeks were significantly higher （ P 〈 0. 05 ）, the rates were 95. 12%, 95. 12%, 56. 1%, 32. 93% respectly at 52 weeks. Conclusion： Telbivudine is effective in patients with chronic hepatitis B.

关 键 词：替比夫定 治疗应用 乙型肝炎E抗原 肝炎 乙型 慢性 疗效 

分 类 号：R512.62[医药卫生—内科学]